HCPLive Network

Pharmacy Times Launches iPad Edition

 

FOR IMMEDIATE RELEASE
Contact: Bill Schu, Group Editorial Director, (609) 716-7777, bschu@mdng.com


Pharmacy Times Launches iPad Edition

Prestigious 113-year-old pharmacy publication among first B-to-B publications available for the iPad.

PLAINSBORO, NJ (September 2, 2010)—Pharmacy Times, the leading journal for retail pharmacists, is proud to debut the pharmacy industry’s first publication designed for the iPad. Featuring the latest pharmacy coverage from our summer issue and an exclusive selection of new multimedia content, the Pharmacy Times iPad edition is available now for free in the iTunes store at http://phrmcyt.ms/bM5Y3x.

The first iPad edition marks the beginning of a new era in the journal’s long history as an industry leader, according to Tighe Blazier, Pharmacy Times President. “Pharmacy Times has been a leader in this industry for a long time,” said Blazier. “One of the key reasons for that success has been our commitment to innovation. This is an exciting next step.”

Through this innovative new platform, Pharmacy Times is able to offer its monthly content—patient counseling and education columns; product and technology news; case studies and clinical trials; and continuing professional education lessons—in ways that transcend the boundaries of print.

Peppered throughout each article are video clips, slide shows, podcasts, infographics, and other digital resources hand-picked by the editors to bring Pharmacy Times content to life. Developed with the media-savvy iPad user in mind, the first issue provides readers with a robust digital publishing experience.

An iPad exclusive “Pharmacy Insights” department covers notable trends in the pharmacy profession, bolstered by additional resources that can be accessed on demand with a simple tap of the screen. Along with new sections, the iPad edition presents the high-caliber information pharmacists expect from Pharmacy Times in a visually stunning, interactive design.

The Pharmacy Times iPad release follows on the heels of the journal’s CE app, which provides mobile access to popular Continuing Education programs from the Pharmacy Times Office of Continuing Professional Education. Both initiatives represent Pharmacy Times’ efforts to embrace new technology that lets readers choose how they access the journal.

Pharmacy Times on the iPad is a fully immersive experience for pharmacists,” said Mike Hennessy, Chairman and CEO of MJH & Associates, which publishes Pharmacy Times. “This is the continuation of the publishing model in which everything is now at the readers’ fingertips. 
 
We’re excited about providing this new choice to pharmacists, and to be the very first industry publication they will read on the iPad.”
 
Pharmacy Times becomes the third MJH & Associates publication to be made available to readers in unique iPad editions, joining MD Magazine and Campaigns & Elections.
 
About Pharmacy Times
 
Pharmacy Times is a clinically based, monthly journal providing practical information pharmacists can use in their everyday practice. Each issue contains articles and features covering medication errors, drug interactions, patient education, pharmacy technology, disease state management, patient counseling, product news, pharmacy law, and specialty pharmacy. Pharmacy Times is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of free continuing pharmacy education.
 
Pharmacy Times, published by Intellisphere, LLC, is a leading provider of health care publishing, research, information, and education. Operating within both traditional and digital media channels, Intellisphere serves the needs of health care professionals through an extensive suite of magazines, journals, e-mail databases, Web sites, events and personal meetings.
 
Intellisphere reaches more than half a million health care professionals through Pharmacy Times, The American Journal of Managed Care, The American Journal of Pharmacy Benefits, MDNG, HCPlive.com, Oncology & Biotech News, Oncology Net Guide, Contemporary Oncology, andOncology Net Guide: Nurses’ Edition.


Further Reading
Fixed-dose tablet is the first sodium glucose cotransporter 2 (SGLT2) inhibitor plus metformin combo product to receive approval in the US.
Orbactiv (oritavancin) is a new antibacterial drug approved to treat patients with acute bacterial skin and skin structure infections.
In 2 recent clinical trials, a treatment for young patients diagnosed with attention deficit hyperactivity disorder reportedly demonstrated benefit over another currently used ADHD medication.
More Reading
$related2$